EP1019065A4 - Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung - Google Patents

Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung

Info

Publication number
EP1019065A4
EP1019065A4 EP98947089A EP98947089A EP1019065A4 EP 1019065 A4 EP1019065 A4 EP 1019065A4 EP 98947089 A EP98947089 A EP 98947089A EP 98947089 A EP98947089 A EP 98947089A EP 1019065 A4 EP1019065 A4 EP 1019065A4
Authority
EP
European Patent Office
Prior art keywords
kits
targeted
formulation
synthesis
variety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98947089A
Other languages
English (en)
French (fr)
Other versions
EP1019065A1 (de
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by East Carolina University filed Critical East Carolina University
Publication of EP1019065A1 publication Critical patent/EP1019065A1/de
Publication of EP1019065A4 publication Critical patent/EP1019065A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98947089A 1997-09-17 1998-09-17 Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung Withdrawn EP1019065A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5916097P 1997-09-17 1997-09-17
US59160P 1997-09-17
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US93972 1998-06-09
PCT/US1998/019419 WO1999013886A1 (en) 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Publications (2)

Publication Number Publication Date
EP1019065A1 EP1019065A1 (de) 2000-07-19
EP1019065A4 true EP1019065A4 (de) 2002-02-20

Family

ID=26738426

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98947089A Withdrawn EP1019065A4 (de) 1997-09-17 1998-09-17 Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung

Country Status (8)

Country Link
EP (1) EP1019065A4 (de)
JP (1) JP2003517428A (de)
KR (1) KR20010030622A (de)
AU (1) AU752531B2 (de)
BR (1) BR9812650A (de)
CA (1) CA2304312A1 (de)
IL (1) IL135140A0 (de)
WO (1) WO1999013886A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20030060438A1 (en) * 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (de) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003268032A1 (en) * 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003287169A1 (en) * 2002-10-18 2004-05-04 Genta Salus Llc Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
AU2003301905A1 (en) * 2002-11-06 2004-06-03 Ludwig Institute For Cancer Research Compositions and methods for treating acute myeloid leukemia
CA2421086A1 (fr) * 2003-02-28 2004-08-28 Institut Pasteur Promoteur de l'arn polymerase i de poulet et son utilisation
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
MX2007005083A (es) 2004-10-29 2007-10-03 Topigen Pharmaceuticals Inc Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
WO2006091841A2 (en) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
WO2009117418A2 (en) 2008-03-17 2009-09-24 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
KR101801407B1 (ko) * 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2015130832A1 (en) * 2014-02-25 2015-09-03 The Regents Of The University Of California Agents for enhancement of production of biofuel precursors in microalgae
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
WO2020036862A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
CN110527630B (zh) * 2019-05-24 2021-04-20 浙江工业大学 一株利用artp诱变技术选育的藤仓赤霉菌突变株及应用
AU2021206510A1 (en) * 2020-01-08 2022-08-04 Microvascular Therapeutics, Llc Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム
AU2022297513A1 (en) * 2021-06-23 2024-01-18 Enclear Therapies, Inc. Method of regulating gene expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210273D0 (en) * 1992-05-13 1992-07-01 Ici Plc Dna
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NYCE J W ET AL: "DNA ANTISENSE THERAPY FOR ASTHMA IN AN ANIMAL MODEL", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 385, 20 February 1997 (1997-02-20), pages 727 - 725, XP000891493, ISSN: 0028-0836 *
NYCE J W: "Insight into adenosine receptor function using antisense and gene-knockout approaches", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 2, February 1999 (1999-02-01), pages 79 - 83, XP004157301, ISSN: 0165-6147 *
See also references of WO9913886A1 *

Also Published As

Publication number Publication date
JP2003517428A (ja) 2003-05-27
EP1019065A1 (de) 2000-07-19
AU9395198A (en) 1999-04-05
WO1999013886A1 (en) 1999-03-25
WO1999013886B1 (en) 1999-04-22
BR9812650A (pt) 2000-08-22
KR20010030622A (ko) 2001-04-16
AU752531B2 (en) 2002-09-19
CA2304312A1 (en) 1999-03-25
IL135140A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
DE69722223D1 (de) Textilweichspülmittelzusammensetzung und anwendungsmethode für die freisetzung von riechstoffderivaten
DE69842237D1 (de) Azeotropische Zusammensetzungen enthaltend 1,1,1,2,3,3,3-Heptafluorpropan und Verfahren, die diese Zusammensetzungen verwenden
BR9812650A (pt) ácidos nucléicos hibridizando marcação múltipla, preparação dos mesmos, composições, formulação, kits e aplicações
FI973363A7 (fi) Nukleiinihappoja sisältävä koostumus, sen valmistus ja käyttö
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
DE69841945D1 (de) Struktur zur Musterbildung, Verfahren zur Musterbildung und deren Anwendung
BR9602933A (pt) Compostos processos para preparação de composto e de composição farmacêutica e composto
DE69836424D1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DE50011656D1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
EP1015470A4 (de) Zusammensetzung und herstellung zum fordern von nukleinsauren
ID28270A (id) Komposisi dan formulasi peptida dan penggunaannya
BR9813997A (pt) Encapsulado hidratado de material ativo, processo para produzir encapsulados hidratados de material ativo, e, produto a base de água
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
DE60043832D1 (de) Zusammensetzung zur Hydrophobierung von Gips, Verfahren zur Herstellung und Anwendung
DE69717155D1 (de) Geschmacksvertraegliches kieselgel, verfahren zu seiner herstellung und diese enthaltende zahnpastezusammenstellung
DE69840097D1 (de) Körnige waschmittelzusammensetzungen und deren herstellung
ID26572A (id) Komposisi penggelap kulit dan rambut
ID19803A (id) Komposisi zat warna rambut dan metoda pengentalannya
DE69828864D1 (de) Pigmentzusammensetzung und damit hergestellte wässrige Pigmentdispersion
ATE308365T1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
DE69915591D1 (de) Zusammensetzungen von 1,1,1,3,3-pentafluorpropan und trans-1,2-dichlorethylen
ID18954A (id) Kopolimer, proses terhidrogenasi daripadanya, dan proses untuk memproduksinya
DE69813488D1 (de) Härtbare Zusammensetzungen und gehärtete Gel-Gegenstände daraus
DE69816274D1 (de) Herstellung von carbonsäureverbindungen und deren derivaten
DE19882553T1 (de) Absorbierende Zusammensetzung, Verfahren zu deren Herstellung und absorbierende Produkte

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020107

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050401

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1029522

Country of ref document: HK